Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Abroad (travel likely)RecruitingPHASE2
Conditions
Aplastic Anemia · de Novo Myelodysplastic Syndrome · Myelodysplastic Syndrome · Previously Treated Myelodysplastic Syndrome
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Tapan M. Kadia)
Study leads
Tapan M Kadia
Principal Investigator
M.D. Anderson Cancer Center